Covered recipient · General Payments record
LYNN A STAGGS
Allopathic & Osteopathic Physicians Physical Medicine & Rehabilitation
General Payments · PY2018–2024
$1,875.12
- Reported across 79 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $360.52 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merz Pharmaceuticals, LLC | $148.68 | 6 |
| ABBVIE INC. | $131.02 | 7 |
| REVANCE THERAPEUTICS, INC. | $36.98 | 1 |
| SI-BONE, INC. | $23.99 | 1 |
| Ipsen Biopharmaceuticals, Inc | $19.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.94 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152227 | CMS |
| ABBVIE INC. | $19.65 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152229 | CMS |
| ABBVIE INC. | $4.24 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152231 | CMS |
| ABBVIE INC. | $12.19 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152233 | CMS |
| ABBVIE INC. | $28.96 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152235 | CMS |
| ABBVIE INC. | $33.41 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152237 | CMS |
| ABBVIE INC. | $7.63 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106152239 | CMS |
| Ipsen Biopharmaceuticals, Inc | $19.85 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091964686 | CMS |
| Merz Pharmaceuticals, LLC | $23.23 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137951768 | CMS |
| Merz Pharmaceuticals, LLC | $25.46 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137951770 | CMS |
| Merz Pharmaceuticals, LLC | $29.57 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137951772 | CMS |
| Merz Pharmaceuticals, LLC | $22.47 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137951774 | CMS |
| Merz Pharmaceuticals, LLC | $24.90 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137951778 | CMS |
| Merz Pharmaceuticals, LLC | $23.05 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137951776 | CMS |
| REVANCE THERAPEUTICS, INC. | $36.98 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147929891 | CMS |
| SI-BONE, INC. | $23.99 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120066993 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.